Current Liabilities decreased faster than Celcuity Inc 's Cash & cash equivalent, this led to improvement in Celcuity Inc 's Quick Ratio to 12.38, Quick Ratio remained below Celcuity Inc average.

Within Medical Laboratories industry 5 other companies have achieved higher Quick Ratio than Celcuity Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 254 to 534.

Explain Quick Ratio?
How much Cash & cash equivalents CELC�s has?
What are CELC�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/CELC/financial-strength

https://api.csimarket.com/api/v1/companies/CELC/fundamentals

https://api.csimarket.com/api/v1/companies/CELC/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

CELC Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	34.19 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	41.26 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	12.38	Subscribe	Subscribe	Subscribe	Subscribe
CELC's Total Ranking	# 534	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-40.23 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-14.76 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Medical Laboratories Industry	# 6
Healthcare Sector	# 190
Overall Market	# 534

Quick Ratio Statistics
High	Average	Low
96.97	22.68	4.23
(Sep 30 2017)		(Jun 30 2025)

Financial Statements
Celcuity Inc 's Current Liabilities	$ 52 Millions	Visit CELC's Balance sheet
Celcuity Inc 's Cash & cash equivalent	$ 643 Millions	Visit CELC's Balance sheet
Source of CELC's Sales		Visit CELC's Sales by Geography

Cumulative Celcuity Inc 's Quick Ratio

CELC's Quick Ratio for the trailling 12 Months

CELC Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	88.85 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	109.11 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	10	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 554	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	6.32 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	9.21 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to CELC Financial Strength Comparisons >> Go to Compare CELC Quick Ratio to its Competitors

On the trailing twelve months basis CELC Cash & cash equivalent soared by 41.26 % in Q3 2026 year on year, faster than Current Liabilities, this led to increase in in Celcuity Inc 's Quick Ratio to 10, Quick Ratio remained below CELC average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Laboratories industry 31 other companies have achieved higher Quick Ratio than Celcuity Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2714 to 3521.

Explain Quick Ratio?
How much Cash & cash equivalents CELC�s has?
What are CELC�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Medical Laboratories Industry	# 32
Healthcare Sector	# 857
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
38.2	12.51	0.74
(Jun 30 2018)		(Mar 31 2025)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Medical Laboratories Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Aclarion Inc	13.58	$ 14.188 Millions	$ 1.044 Millions
Celcuity Inc	12.38	$ 642.703 Millions	$ 51.925 Millions
Miragen Therapeutics Inc	11.70	$ 955.206 Millions	$ 81.673 Millions
Billiontoone Inc	9.26	$ 561.512 Millions	$ 60.637 Millions
Absci Corp	8.70	$ 173.729 Millions	$ 19.958 Millions
Maxcyte inc	6.36	$ 101.280 Millions	$ 15.916 Millions
Personalis Inc	5.17	$ 254.841 Millions	$ 49.274 Millions
Veracyte Inc	4.40	$ 370.532 Millions	$ 84.209 Millions
Castle Biosciences Inc	4.11	$ 277.665 Millions	$ 67.612 Millions
Fulgent Genetics Inc	4.07	$ 292.739 Millions	$ 71.877 Millions
Omniab Inc	3.81	$ 64.210 Millions	$ 16.853 Millions
Guardant Health Inc	2.75	$ 1,026.848 Millions	$ 373.165 Millions
Incyte Corporation	2.68	$ 3,854.572 Millions	$ 1,437.818 Millions

Date modified: 2026-11-06T10:08:18+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.